2022 Highlights

Montefiore Einstein Neurological Sciences

Comprising the Saul R. Korey Department of Neurology and the Leo M. Davidoff Department of Neurological Surgery, our Neurological Sciences Program is driven by a shared mission to provide comprehensive, multidisciplinary care for patients with disorders affecting the nervous system, including the brain, spinal cord and peripheral nerves. Each department endeavors to improve service and optimize the patient journey using a patient-centered approach, engage in high-impact translational research and participate in the education and mentorship of students, residents, fellows and faculty. 

DATA & STATISTICS

2022 by the numbers

35%

increase in neurology outpatient visits since 2017

62%

increase in neurological surgery visits since 2018

8%

increase in neurological surgery admissions

5,000+

neurosurgical procedures over the past 4 years

Montefiore Einstein's Comprehensive Stroke center achieves the Gold Plus Award

Montefiore Einstein’s Moses Campus is honored to be recognized by the American Heart Association with the 2021 “Get with the Guidelines – Stroke GOLD PLUS with Honor Roll Elite” award, for commitment to prioritizing quality care for stroke patients.

An ongoing commitment to research and mentorship

Founded in 2012 and currently led by Emad N. Eskandar, MD, the Neurosurgeon Research Career Development Program (NRCDP) is an NIH-funded K12 program whose mission is to develop a cadre of diverse neurosurgeon scientists at institutions throughout the country. In the nine years since its inception, the highly successful and expanding program has reviewed applications from 125 individuals at 60 different institutions and has supported 26 scholars. 

In a recent review, it was discovered that 85% of NRCDP scholars successfully obtained subsequent independent federal funding and continue to lead active, productive research efforts as neurosurgeon-scientists. This ethos animates the faculty, residents and students in the Departments of Neurology and Neurosurgery who collectively strive to improve patient outcomes through basic, translational and clinical research.

Advancing neurological surgery care through clinical trials

Through innovative clinical research, our scientists and researchers are at the forefront of discovery, offering breakthroughs in atypical meningiomas and pituitary adenoma. Faculty in the Department of Neurological Surgery are involved in nearly 80 research protocols studying a broad range of disorders, including neurovascular disease, epilepsy, movement disorders, spinal disease, brain tumors and neurosurgical disorders affecting infants and children.

US IDE Study of the Contour NEurovasCular System™ for IntraCranial Aneurysm Repair (NECC)

The Cerus contour device is a new endosaccular flow disruptor designed to treat wide-necked bifurcation aneurysms. Historically, aneurysms in this location have been treated with open surgical clipping or stent-assisted coiling, which requires the need of long-term dual antiplatelet therapy. The Cerus contour device offers a minimally invasive alternative without the need for long-term antiplatelet therapy. Montefiore is one of a handful of select hospitals in the country participating in the trial designed to study the safety and efficacy of the device. If you have any questions or potential candidates, please contact Dr. David Altschul.

The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma (STEM) (STEM)

Chronic subdural hematoma is a common disease that affects elderly patients. Traditional treatment involves surgical evacuation; however, these treatments come with a high complication rate, including the need for multiple surgeries. Minimally invasive treatments have been discovered in the form of middle meningeal artery embolization. Montefiore is one of some 20 centers in the country assessing the safety and efficacy of patients with middle meningeal artery embolization with or without surgery for the treatment of chronic subdural hematoma. If you have any questions or potential candidates, please contact Dr. David Altschul.

Intractable Migraine Study

Intractable migraine disorder is a serious illness that affects many young people and impacts their ability to work and participate in society. We are researching the theory that the cause of this illness is vascular in nature, due to an imbalance of the vasomotor tone of the extracranial vasculature. We are currently in the study’s first phase: recruiting patients and injecting vasodilator medications into these arteries to prove migraine headaches can be triggered. Once proved, we can then move to the next phase of the study, which will be to embolize these arteries as a potential modality for treatment.

0

Evolve, Surpass Evolve Flow Diverter Trial

The Surpass Evolve Flow Diverter System is indicated for the endovascular treatment of adults (age 18 or above) with unruptured saccular wide-neck or fusiform intracranial aneurysms ≤ 12 mm for treatment in vessel diameters between 1.75-5.0mm. This next generation flow wire diverter provides a smooth delivery even in tortuous anatomy, provides reliable deployment and optimizes diversion by maintaining a high density of the surpass streamline flow diverter regardless of having fewer wires than the old generations flow diverters.

Citadel Trial Citadel Embolization Device Study

In this study, use of the Citadel Embolization Device will be limited to a population of patients with unruptured or ruptured wide-neck aneurysms who meet all study eligibility criteria. The Citadel Embolization Device is intended to endovascularly obstruct or occlude blood flow in intracranial aneurysms. The Citadel Device is Coil-like treatment that simplifies the procedure that has shown better framing and neck coverage than Target Detachable Coil.

TLIF Clinical Study Infuse Bone Graft

This is a research study to evaluate the safety and effectiveness of the device Infuse™ Bone Graft (infuse) when used in a TLIF surgery in combination with an intervertebral body fusion device and an implantable, metal rod and screw system, for the possible treatment of degenerative disc disease of the spine. Infuse Bone Graft is investigational in this study because it is being tested and is not approved by the United States Food and Drug Administration (FDA) for use in a TLIF procedure. Instead of the investigational device, patients have a 1 in 3 chance of receiving standard TLIF surgery without the Infuse Bone Graft, this Control Group is used to compare results to the investigational device.

Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases

Drs. Celina Crisman and Benjamin Himes are working with Dr. Nitin Ohri, a radiation oncologist principle investigator, on a clinical trial to assess the benefit of pre- vs. postoperative SRS in the control of brain metastasis. Surgery and stereotactic radiosurgery (SRS) remain the mainstays of therapy for oligometastatic cancer to the brain. Traditionally, surgery has preceded SRS in order to establish a definitive diagnosis and reduce the size of the radiation field. However, this approach carries the possibility of seeding tumor cells in the resection cavity and CSF spaces, potentially increasing the risk of recurrence or the development of leptomeningeal disease. This randomized trial will directly answer the question of whether preoperative SRS reduces the risk of recurrence or disease spread, which will directly inform clinical practice.

CLINICAL TRIALS

Advancing neurological care through clinical trials

Our scientists and researchers are paving the way for novel treatments and diagnostic breakthroughs through our innovative clinical research, which includes work in cerebrovascular diseases, epilepsy, migraine, sleep wake disorders and more.

NIH Strokenet for Acute Interventional Stroke Trials

Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

Statins In Intracerbral Hemorrhage (SATURN)

A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

An Open Label Study of FT218 in Subjects With Narcolepsy (RESTORE)

Michael J. Thorpy, MD

Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies

Richard B. Lipton, MD

Atogepant for the Preventive Treatment of Migraine

Richard B. Lipton, MD

Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome

Richard B. Lipton, MD

Efficacy of erenumab in chronic migraine patients with and without ictal allodynia

Richard B. Lipton, MD

Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study

Richard B. Lipton, MD

Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant

Richard B. Lipton, MD

Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II

Richard B. Lipton, MD

Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study

Richard B. Lipton, MD

Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial

Richard B. Lipton, MD

Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension

Richard B. Lipton, MD

Basic and translational research

The Department of Neurological Surgery includes four outstanding scientists performing translational research to develop new understandings of specific neurological conditions. This research is aimed at understanding the basis of cognition and its impairment in Parkinson disease, understanding the mechanisms underlying learning and their derangement in substance use or behavioral addictions, developing neural prosthetics for the treatment of blindness and developing a better understanding of the biology and immunology of glioblastoma in an effort to develop more effective treatments.

Team News

Updates and additions to our Neurological Surgery faculty

Benjamin T. Himes, MD, PhD

Attending Physician
Assistant Professor, Neurological Surgery

Mandana Behbahani, MD

Attending Physician
Assistant Professor, Neurological Surgery

Celina M. Crisman, MD, MPH

Attending Physician
Assistant Professor, Leo M. Davidoff Department of Neurological Surgery

Yaroslav (Jacob) Gelfand, MD

Attending Physician
Assistant Professor, Leo M. Davidoff Department of Neurological Surgery

Saikiran Murthy, DO

Attending Physician
Assistant Professor, Leo M. Davidoff Department of Neurological Surgery

Jinan Behnan, PhD

Assistant Professor, Leo M. Davidoff Department of Neurological Surgery

Team News

Updates and additions to our Neurology faculty

Perveen K. Chattha, MD

Attending Physician, Neurology
Assistant Professor, Neurology

Amina Khalid, MD

Attending Physician, Neurology
Assistant Professor, Neurology

Oleg Otlivanchik, MD, PhD

Attending Physician, Department of Neurology
Attending Physician, Stern Stroke Center
Stroke Neurohospitalist Liaison

Ji-ae Lee, MD

Attending Physician, Neurology

Cast your vote

Polls on Doximity close soon. We hope you’ll consider nominating Montefiore Einstein Neurological Sciences for the U.S. News & World Report Best Hospitals survey.

Contact us

Mark F. Mehler MD, Chair, Neurology
mark.mehler@einsteinmed.edu

 

Emad Eskandar MD, MBA, Chair, Neurological Surgery
eeskanda@montefiore.org

Montefiore Einstein Neurology
Montefiore Einstein Neurological Surgery